KR102870956B1 - 조현병의 치료를 위한 일로페리돈 - Google Patents

조현병의 치료를 위한 일로페리돈

Info

Publication number
KR102870956B1
KR102870956B1 KR1020177026225A KR20177026225A KR102870956B1 KR 102870956 B1 KR102870956 B1 KR 102870956B1 KR 1020177026225 A KR1020177026225 A KR 1020177026225A KR 20177026225 A KR20177026225 A KR 20177026225A KR 102870956 B1 KR102870956 B1 KR 102870956B1
Authority
KR
South Korea
Prior art keywords
iloperidone
patients
relapse
day
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177026225A
Other languages
English (en)
Korean (ko)
Other versions
KR20170118830A (ko
Inventor
미하엘 에이치. 폴리머로폴로스
커르트 디. 볼프강
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Publication of KR20170118830A publication Critical patent/KR20170118830A/ko
Application granted granted Critical
Publication of KR102870956B1 publication Critical patent/KR102870956B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177026225A 2015-02-17 2016-02-17 조현병의 치료를 위한 일로페리돈 Active KR102870956B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US62/117,173 2015-02-17
US201562172436P 2015-06-08 2015-06-08
US62/172,436 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
KR20170118830A KR20170118830A (ko) 2017-10-25
KR102870956B1 true KR102870956B1 (ko) 2025-10-16

Family

ID=55532275

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026225A Active KR102870956B1 (ko) 2015-02-17 2016-02-17 조현병의 치료를 위한 일로페리돈

Country Status (9)

Country Link
US (2) US10441580B2 (enExample)
EP (1) EP3258935B1 (enExample)
JP (1) JP6885649B2 (enExample)
KR (1) KR102870956B1 (enExample)
CN (2) CN116211857A (enExample)
BR (1) BR112017017608A2 (enExample)
CA (1) CA2976383C (enExample)
ES (1) ES2870498T3 (enExample)
WO (1) WO2016134049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
JP2026504721A (ja) * 2022-12-19 2026-02-09 バンダ・ファーマシューティカルズ・インコーポレイテッド 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン
WO2024249952A1 (en) 2023-06-02 2024-12-05 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132866A1 (en) * 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2305656T3 (da) 2001-08-31 2013-02-11 Novartis Ag Optiske isomerer of en iloperidonmetabolit
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
KR20100099292A (ko) * 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
EP2785347A1 (en) * 2011-12-02 2014-10-08 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
IN2014DN08495A (enExample) 2012-03-14 2015-05-08 Vanda Pharmaceuticals Inc
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132866A1 (en) * 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Am. J. Psychiatry, 제167권, 제676-685면 (2010년)*

Also Published As

Publication number Publication date
HK1248551A1 (zh) 2018-10-19
BR112017017608A2 (en) 2018-05-08
US20180021324A1 (en) 2018-01-25
JP2018505901A (ja) 2018-03-01
CN116211857A (zh) 2023-06-06
CA2976383C (en) 2023-05-23
ES2870498T3 (es) 2021-10-27
EP3258935A1 (en) 2017-12-27
CN107249586A (zh) 2017-10-13
US10441580B2 (en) 2019-10-15
EP3258935B1 (en) 2021-04-07
JP6885649B2 (ja) 2021-06-16
WO2016134049A1 (en) 2016-08-25
CA2976383A1 (en) 2016-08-25
US20190388412A1 (en) 2019-12-26
KR20170118830A (ko) 2017-10-25
US10987346B2 (en) 2021-04-27

Similar Documents

Publication Publication Date Title
Bowden et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Vieta et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial
AU2012321110B2 (en) Combination treatment
TW201919624A (zh) 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
US10987346B2 (en) Iloperidone for the treatment of schizophrenia
Chrysant et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis
JP2024056908A (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
C Nelson et al. Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment
JP2015522077A5 (enExample)
US20070185080A1 (en) Pharmaceutical Compositions
WO2005070427A1 (en) Compounds for the sustained reduction of body weight
Marques da Silva Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan
Adams et al. Evaluation and pharmacologic approach to patients with resistant hypertension
HK1248551B (en) Iloperidone for the treatment of schizophrenia
Placebo-Controlled Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia
JP2018507216A (ja) 多発性骨髄腫に対するパノビノスタット投与量
Dubovsky et al. P. 3. c. 055 Asenapine: short-term tolerability, safety, and pharmacokinetic profile in older patients with psychosis
CN102149389A (zh) 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途
CN102791265A (zh) 决奈达隆或其药学上可接受的盐在制备用于胺碘酮停止后不久给药的药物中的用途
WO2021255438A1 (en) Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome
Rajiv et al. First-line Therapy in Status Epilepticus
US20060094709A1 (en) Methods for the treatment of bipolar disorder using carbamazepine
US20050124601A1 (en) Methods for the treatment of bipolar disorder using carbamazepine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)